SCHEMBL17870962

SCHEMBL17870962

O=C(C=CCl)N1C(=O)C[C@H]1c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.40
ALDH1A1 P00352 2/20 0.37
SIGMAR1 Q99720 1/20 0.37
GSK3B P49841 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
YAP1 P46937 1/20 0.36
TEAD4 Q15561 1/20 0.36
SCD O00767 1/20 0.36
ITGB1 P05556 1/20 0.35
ITGA5 P08648 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
MITF O75030 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17881949 1.00 RIPK1 (0.52) RIPK1L3MBTL1ALDH1A1SIGMAR1GSK3B
SCHEMBL19471101 1.00 RIPK1 (0.52) RIPK1L3MBTL1ALDH1A1SIGMAR1GSK3B
SCHEMBL23758948 0.79 RIPK1 (0.52) RIPK1L3MBTL1ALDH1A1KMT2AITGB1
SCHEMBL12620555 0.75 RIPK1 (0.56) RIPK1L3MBTL1ALDH1A1SIGMAR1KMT2A
SCHEMBL19511247 0.74 RIPK1 (0.56) RIPK1SIGMAR1KMT2AYAP1TEAD4
SCHEMBL1801255 0.73 L3MBTL1 (0.57) RIPK1L3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL14071753 0.71 RAB9A (0.51) L3MBTL1ALDH1A1KMT2AMEN1GAA
SCHEMBL17870961 0.70 RIPK1 (0.48) RIPK1L3MBTL1ALDH1A1SIGMAR1KMT2A
SCHEMBL19471093 0.70 RIPK1 (0.48) RIPK1L3MBTL1ALDH1A1SIGMAR1KMT2A
SCHEMBL248353 0.69 RIPK1 (0.61) RIPK1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11478438-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2022-10-25 US disclosed
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 US disclosed
CN-107108492-B Cell necrosis inhibitor 北京生命科学研究所 2021-03-19 CN disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200182617-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-11 US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 US disclosed
US-10555920-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-11 US disclosed
US-20190038578-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2019-02-07 US disclosed
US-10092529-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-10-09 US disclosed
EP-3224245-B1 NECROSIS INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2018-09-12 EP disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
US-20170304237-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-26 US disclosed
EP-3224245-A1 NECROSIS INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2017-10-04 EP disclosed
WO-2016101887-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304237-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885L3MBTL1 2892/4885ALDH1A1 3900/4885
US-11478438-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885L3MBTL1 3530/4885ALDH1A1 4104/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL RIPK1 2/4885L3MBTL1 1239/4885ALDH1A1 2786/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL RIPK1 2/4885L3MBTL1 1239/4885ALDH1A1 2786/4885
US-20190038578-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885L3MBTL1 3530/4885ALDH1A1 4104/4885
US-10092529-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885L3MBTL1 2892/4885ALDH1A1 3900/4885
US-10555920-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885L3MBTL1 3530/4885ALDH1A1 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.